Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
The latest available 13F covers holdings as of Jun 30, 2026 (Q2 2026) and was filed Aug 13, 2026. Quarter-end snapshot, not a live trade.
Disclosed 13F value
$22.1B
sum of reported positions
Reported positions
660
Changes vs prior quarter
624
41 new · 54 exited
Filings on record
9
Q2 2026, Q1 2026, Q4 2025, Q3 2025, Q2 2025, Q1 2025, Q4 2024, Q3 2024, Q2 2024
Across 354 measured positions in 8 quarters, the typical new or larger position finished +0.0 pts against the S&P 500 and 50% finished ahead of it. For scale, across all 501 funds with a result: −2.2 pts typical, 44% ahead.
Measured on each position this fund reported as new or larger, from the first close after the filing became public, against the S&P 500, 90 days later. Sales are not scored. History, not a forecast; it shows what the stocks did, not what the fund knew.
Total value of the 13F each quarter. It moves with prices as well as with what the fund bought or sold, so a rise is not necessarily a purchase.
Comparison uses this manager's immediately preceding 13F-HR. Puts and calls are separate lines. Share counts drive classification; reported value also moves with price.Methodology
Change in the reported value against the quarter before.
Weights are within the disclosed 13F portfolio, for the ten largest lines.
| Q1 2026 | Q2 2026 | |
|---|---|---|
| Reported value | $19.2B | $22.1B |
| Positions | 673 | 660 |
| Biggest line | — | NVIDIA 6% |
| 2.62M |
| $936M |
| 4.2% |
| 1.69M | $639M | 2.9% |
| 2.6M | $618M | 2.8% |
| 423K | $488M | 2.2% |
| 402K | $482M | 2.2% |
| 658K | $382M | 1.7% |
| 963K | $328M | 1.5% |
| 713K | $309M | 1.4% |
| 843K | $297M | 1.3% |
| 1.16M | $293M | 1.3% |
| 606K | $289M | 1.3% |
| 761K | $229M | 1.0% |
| 644K | $221M | 1.0% |
| 379K | $194M | 0.9% |
| 1.42M | $182M | 0.8% |
| 1.35M | $179M | 0.8% |
| 544K | $178M | 0.8% |
| 2.01M | $176M | 0.8% |
| 347K | $174M | 0.8% |
| 429K | $171M | 0.8% |
| 210K | $159M | 0.7% |
| 271K | $152M | 0.7% |
Eyepoint (EYPT)
674K → 788K shares (+17%)
Clean Harbors (CLH)
37K → 38K shares (+2%)
W. W. Grainger (GWW)
6,643 → 8,266 shares (+24%)
Howmet Aerospace (HWM)
42K → 42K shares (−2%)
Colgate-Palmolive (CL)
128K → 121K shares (−5%)
Bicara Therapeutics (BCAX)
239K → 373K shares (+56%)
Dover Corporation (DOV)
52K → 49K shares (−5%)
ITT Inc. (ITT)
48K → 56K shares (+16%)
Tenax Therapeutics (TENX)
750K shares
Avnet (AVT)
49K → 122K shares (+148%)
Dexcom (DXCM)
83K → 160K shares (+94%)
Principal Financial Group (PFG)
14K → 100K shares (+603%)
Darling Ingredients (DAR)
143K → 196K shares (+37%)
APOGEE THERAPEUTICS INC
224K → 80K shares (−64%)
MetLife (MET)
130K → 125K shares (−4%)
State Street Corporation (STT)
52K → 62K shares (+19%)
Centene Corporation (CNC)
35K → 163K shares (+368%)
Bloom Energy (BE)
16K → 34K shares (+109%)
UPS (UPS)
91K → 96K shares (+5%)
Sionna Therapeutics (SION)
237K → 233K shares (−2%)
FedEx (FDX)
23K → 31K shares (+37%)
Olema Pharmaceuticals (OLMA)
760K → 751K shares (−1%)
Nurix Therapeutics (NRIX)
534K → 378K shares (−29%)
Mercury General (MCY)
67K → 85K shares (+27%)
Marsh McLennan (MRSH)
52K → 54K shares (+5%)
